Debt, Deficits & Disaster: The Bond Market Crisis
Not Wall Street, But AI: The Real Force Democratizing Finance Across America
When Flooding Pays: A New Financial Bet
Breakfast for Life How Local Diners and Hardware Stores are Outsmarting Amazon
Fundamentals for Revvity, Inc.
Business Operations:
Sector: HealthcareIndustry: Diagnostics & Research
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Revenue projections:
RVTY's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.
Financial Ratios:
| currentRatio | 1.682000 |
|---|---|
| forwardPE | 14.435623 |
| debtToEquity | 46.869000 |
| earningsGrowth | 0.125000 |
| revenueGrowth | 0.059000 |
| grossMargins | 0.547740 |
| operatingMargins | 0.200670 |
| trailingEps | 2.060000 |
| forwardEps | 6.004590 |
A current ratio of 1.682 for RVTY implies that the company has ample liquidity to meet its short-term debts. RVTY's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
RVTY's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
Revvity, Inc.'s positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
RVTY's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.
Price projections:
Price projections for Revvity, Inc. have been revised lower over time, signaling a more cautious outlook from analysts. The gradual downward trend indicates that expectations for the company's growth may be softening.
Insider Transactions:
7 Revvity, Inc. shares were sold in recent transactions, with market price at 96.41142817905971.Throughout the period under consideration, no sell transactions were recorded.The higher number of buys versus sells near RVTY's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.
Recommendation changes over time:
A recent buy bias from analysts toward RVTY may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that RVTY might be an appealing option for those looking to grow their wealth through stock market investments.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst technicals.
Latest Regulatory Filings for SP5
Companies with the best and the worst fundamentals.
Before They Can Walk, They're Invested: How Trump Accounts Are Transforming Financial Culture
The Appalachian Energy Reboot: Inside the Unexpected Nuclear Startup Boom
Theatrical Finance: Credit Unions Use Drama to Attract Youth